Xia Feng, Chang Xiangyang, Zhang Yinfa, Wang Lizhong, Xiao Fei
Department of Anaesthesia, Jiaxing University Affiliated Women and Children Hospital, Jiaxing, Zhejiang, China.
BMC Anesthesiol. 2018 Jun 23;18(1):74. doi: 10.1186/s12871-018-0528-2.
Studies have shown that dexmedetomidine (Dex) can prolong the duration of analgesia when added to local anaesthetic as an adjuvant in a central or peripheral nerve block. We hypothesized that intrathecal Dex can reduce the ED95 of spinal hyperbaric bupivacaine. Therefore, we conducted this prospective, double-blinded, randomized study to verify our hypothesis.
Ninety patients were allocated into the Dexmedetomidine group (received bupivacaine + 5 mcg dexmedetomidine) and the Control group (received bupivacaine + the same volume of saline) using a double-blinded and randomized method. The first patient in each group received 5 mg of IT hyperbaric bupivacaine, and the next dose for the following patient was determined by the probability of successful anaesthesia of the previous neighbouring dose. An improved up-down sequence allocated method combined with probit analysis was used to determine the ED95 of intrathecal hyperbaric bupivacaine for the two groups.
The ED95 and 95% confidence intervals (95% CI) of IT hyperbaric bupivacaine of the Dex group and Control group were 8.4 mg (95% CI, 6.5~ 13.8 mg) and 12.1 mg (95% CI, 8.3~ 312.8 mg), respectively. The duration of sensory block was longer in the Dex group than in the Control group (110.3 ± 35.3 vs 67.5 ± 26.2). The duration of analgesia was also longer in the Dex group than in the Control group (224.9 ± 45.4 vs 155.1 ± 31.6). The consumption of postoperative rescued sufentanil was significantly higher in the Control group than in the Dex group.
Intrathecal 5 mcg dexmedetomidine potentiated hyperbaric bupivacaine antinociception by 31% in spinal anaesthesia for patients undergoing caesarean section.
We registered this study in a Chinese Clinical Trial Registry (ChiCTR) centre on Nov 1st 2016 and received the registration number: ChiCTR-IPR-16009699 .
研究表明,在中枢或外周神经阻滞中,右美托咪定(Dex)作为佐剂添加到局部麻醉剂中可延长镇痛时间。我们假设鞘内注射Dex可降低腰麻用重比重布比卡因的ED95。因此,我们进行了这项前瞻性、双盲、随机研究以验证我们的假设。
采用双盲随机方法将90例患者分为右美托咪定组(接受布比卡因 + 5μg右美托咪定)和对照组(接受布比卡因 + 等量生理盐水)。每组的第一名患者接受5mg腰麻用重比重布比卡因,下一名患者的剂量根据前一相邻剂量麻醉成功的概率确定。采用改进的上下顺序分配法结合概率分析来确定两组腰麻用重比重布比卡因的ED95。
右美托咪定组和对照组腰麻用重比重布比卡因的ED95及95%置信区间(95%CI)分别为8.4mg(95%CI,6.513.8mg)和12.1mg(95%CI,8.3312.8mg)。右美托咪定组的感觉阻滞时间长于对照组(110.3±35.3对67.5±26.2)。右美托咪定组的镇痛时间也长于对照组(224.9±45.4对155.1±31.6)。对照组术后补救性舒芬太尼的消耗量显著高于右美托咪定组。
剖宫产患者腰麻时,鞘内注射5μg右美托咪定可使重比重布比卡因的镇痛作用增强31%。
我们于2016年11月1日在中国临床试验注册中心(ChiCTR)注册了本研究,注册号为:ChiCTR-IPR-16009699。